Holen Sie sich die Stockscreener-App
6.17
2.49%
0.15
Schlusskurs vom Vortag:
$6.02
Offen:
$5.93
24-Stunden-Volumen:
371.76K
Relative Volume:
2.30
Marktkapitalisierung:
$210.79M
Einnahmen:
$38.79M
Nettoeinkommen (Verlust:
$-6.57M
KGV:
-25.92
EPS:
-0.238
Netto-Cashflow:
$-8.52M
1W Leistung:
-17.40%
1M Leistung:
-30.44%
6M Leistung:
-29.08%
1J Leistung:
-4.04%
1-Tages-Spanne:
$5.90
$6.50
1-Wochen-Bereich:
$5.90
$7.735
52-Wochen-Spanne:
$4.68
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Firmenname
Fennec Pharmaceuticals Inc
Sektor
Branche
Telefon
(919) 636-4530
Adresse
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
6.17 | 210.79M | 38.79M | -6.57M | -8.52M | -0.238 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Eingeleitet | B. Riley Securities | Buy |
| 2026-01-09 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-08 | Fortgesetzt | Craig Hallum | Buy |
| 2020-06-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Eingeleitet | Goldman | Buy |
Alle ansehen
Fennec Pharmaceuticals Inc Aktie (FENC) Neueste Nachrichten
Fennec Pharmaceuticals Hits Day Low of CAD 8.26 Amid Price Pressure - Markets Mojo
Day Trade: Will Fennec Pharmaceuticals Inc benefit from AI trendsEarnings Summary Report & Short-Term High Return Ideas - baoquankhu1.vn
Adherex Technologies (FENC) to Release Earnings on Wednesday - Defense World
Fennec Pharmaceuticals Reports Record 2025 PEDMARK® Sales Growth and Financial Results, Highlights Pipeline and Global Expansion - Minichart
(FENC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Fennec Pharmaceuticals Reports Record FY2025 Net Product Sales of $44.6M, Q4 Sales $13.8M - TradingView
Record PEDMARK growth but wider 2025 loss for Fennec (NASDAQ: FENC) - Stock Titan
Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada
Fennec Pharmaceuticals misses Q4 estimates on earnings and revenue - MSN
Adherex Technologies Q4 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Fennec Pharmaceuticals(FENC.US) Q4 2025 Earnings Conference - Moomoo
Adherex Technologies Q4 Earnings Call Highlights - MarketBeat
Adherex Technologies (NASDAQ:FENC) Announces Earnings Results - MarketBeat
Earnings call transcript: Fennec Pharmaceuticals Q4 2025 misses expectations - Investing.com
Craig-Hallum Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating - Moomoo
Fennec Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fennec Pharmaceuticals posts fiscal year 2025 financial results and business update - Traders Union
Fennec Pharmaceuticals Inc. (FENC) Misses Q4 EPS Estimates - AlphaStreet
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Fennec Pharmaceuticals (NASDAQ:FENC) Reports Q4 2025 Revenue Growth but Misses Earnings Estimates - ChartMill
Fennec Pharmaceuticals Posts Record PEDMARK Sales and Broadens Clinical Footprint in 2025 - TipRanks
FENNEC PHARMACEUTICALS ($FENC) Releases Q4 2025 Earnings - Quiver Quantitative
Fennec Pharmaceuticals misses Q4 estimates on earnings, revenue - Investing.com UK
Fennec Pharmaceuticals misses Q4 estimates on earnings, revenue By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Cancer hearing-loss drug lifts Fennec sales 50% as debt hits zero - Stock Titan
Fennec Pharmaceuticals earnings are imminent; these most accurate analysts revise forecasts ahead of earnings call - MSN
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
FRX.CA Forecast, Price Target & Analyst Ratings | FENNEC PHARMACEUTICALS INC (TSX:FRX) - ChartMill
Fennec Pharmaceuticals (TSX:FRX) Shares Drift Below Key Average Level - Kalkine Media
Fennec Pharma (TSX:FRX) Falls Below Key Average in TSX Index - Kalkine Media
Fennec to Report 2025 Results as Global Rollout of PEDMARK Advances - The Globe and Mail
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat
Retail Surge: Is Fennec Pharmaceuticals Inc still a buy after recent gains2026 Big Picture & Reliable Trade Execution Plans - baoquankhu1.vn
Breakout Zone: Can Fennec Pharmaceuticals Inc stock outperform in a bear marketTrend Reversal & Long-Term Capital Growth Ideas - baoquankhu1.vn
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 - The Manila Times
Fennec Pharmaceuticals Inc. - Mena FN
Fennec schedules March 24 call to unveil full-year 2025 numbers - Stock Titan
Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033 - Law360
B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla Settlement - marketscreener.com
Fennec settles patent case with Cipla over generic PEDMARK By Investing.com - Investing.com Australia
FENC Stock Quote - RichTv
Fennec Pharmaceuticals (FENC) delays Cipla generic PEDMARK rival until 2033 - Stock Titan
Fennec Pharmaceuticals announces settlement agreement resolving Pedmark patent litigation - marketscreener.com
Fennec settles patent case with Cipla over generic PEDMARK - Investing.com
Fennec Pharmaceuticals Announces Settlement Agreement Resolving Pedmark Patent Litigation - TradingView
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation - The Manila Times
Patent deal delays PEDMARK generic, drug for chemo hearing loss, to 2033 - Stock Titan
(FRX) Technical Patterns and Signals (FRX:CA) - Stock Traders Daily
Adherex Technologies (NASDAQ:FENC) Cut to Buy at Wall Street Zen - MarketBeat
Liquidity Mapping Around (FENC) Price Events - Stock Traders Daily
Finanzdaten der Fennec Pharmaceuticals Inc-Aktie (FENC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fennec Pharmaceuticals Inc-Aktie (FENC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Raykov Rosty | Director |
Mar 02 '26 |
Sale |
8.36 |
10,079 |
84,260 |
103,996 |
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):